MIRACLE ICD

MIRACLE ICD

Abbreviation for:
Multicentre InSync™ Randomized Clinical Evaluation Implantable Cardioverter Defibrillator
Mentioned in ?
References in periodicals archive ?
Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial.
Medtronic has supported seven major heart failure studies that have contributed to guidelines, including SCD-HeFT, REVERSE, MIRACLE, MIRACLE ICD, MIRACLE ICD II, MUSTIC, and CARE HF studies.
MIRACLE / MIRACLE ICD (Multicenter InSync / ICD Randomized Clinical Evaluation) studies: initiated in 1998 and 1999, respectively, evaluated NYHA Class III, IV patients for six months and demonstrated significant improvements in quality of life and cardiac function.
The results reinforce evidence from earlier Medtronic-supported trials, such as MUSTIC, MIRACLE and MIRACLE ICD, that have shown dramatic benefits of CRT for many heart failure patients, including improved exercise capacity, quality of life and clinical symptoms.
Other major clinical trials supported by Medtronic such as MUSTIC, MIRACLE and MIRACLE ICD have shown dramatic benefits of CRT for many heart failure patients, including improved exercise capacity, quality of life and clinical symptoms.
The study, called MIRACLE ICD II, evaluated the use of cardiac resynchronization therapy defibrillators in patients with mild symptoms, and showed that these patients demonstrated significant improvement in both cardiac structure and function, as well as improvements in their overall clinical response.
In the past decade, Medtronic has enrolled nearly 9,000 patients in more than 20 heart failure clinical studies, including MUSTIC, MIRACLE, MIRACLE ICD, SCD-HeFT, CARE-HF, and BLOCK HF.
Since 1997, we have supported 20 heart failure clinical studies, including MIRACLE, MIRACLE ICD, SCD-HeFT and CARE-HF.
Evidence supporting the benefits of cardiac resynchronization therapy (CRT) for heart failure patients continues to mount, with results of the MIRACLE ICD clinical study published in the May 28 issue of the Journal of the American Medical Association (JAMA).
Other major clinical trials sponsored by Medtronic such as MUSTIC, MIRACLE and MIRACLE ICD have shown dramatic benefits for many heart failure patients who receive cardiac resynchronization therapy, including improved exercise capacity, quality of life and clinical symptoms.
The effectiveness of cardiac resynchronization therapy was proven in the MIRACLE and MIRACLE ICD clinical trials.
With the benefits of cardiac resynchronization therapy for many heart failure patients now well-documented thanks to landmark clinical trials such as MIRACLE and MIRACLE ICD, physicians are anxiously awaiting additional medical data that further support this breakthrough therapy.